REGN: Regeneron Pharmaceuticals Inc. Stocks News on August 23, 2025

REGN

Zacks

a day ago

The Zacks Analyst Blog Highlights Health Care Select Sector SPDR, SPDR S&P 500 ETF Trust, UnitedHealth, Regeneron, CVS Health and Novo Nordisk

J&J signs $2bn incumbency deal at CDMO Fujifilm’s new hub

REGN

Pharmaceutical Technology

2 days ago

J&J signs $2bn incumbency deal at CDMO Fujifilm’s new hub

REGN

Zacks

2 days ago

FDA Extends Review Period of REGN's Submission for Eylea HD

Novo’s facility issues delay FDA decisions on Regeneron’s Eylea HD

REGN

Pharmaceutical Technology

2 days ago

Novo’s facility issues delay FDA decisions on Regeneron’s Eylea HD

J&J to invest $2 billion to boost US manufacturing as drug tariffs loom

REGN

Reuters

2 days ago

J&J to invest $2 billion to boost US manufacturing as drug tariffs loom

FDA Pushes Back Eylea HD Review; Regeneron Still Gains

REGN

GuruFocus.com

2 days ago

FDA Pushes Back Eylea HD Review; Regeneron Still Gains

REGN

MT Newswires

3 days ago

Regeneron Pharmaceuticals Says FDA Extends Action Dates for Eylea HD to Q4

EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension

REGN

GlobeNewswire

3 days ago

EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension

Will EXEL's Share Repurchase Program Boost Value for Investors?

REGN

Zacks

4 days ago

Will EXEL's Share Repurchase Program Boost Value for Investors?

Global Ophthalmology Drugs Market to Reach USD 26.28 Billion by 2030 | MarketsandMarkets™

REGN

GlobeNewswire

5 days ago

Global Ophthalmology Drugs Market to Reach USD 26.28 Billion by 2030 | MarketsandMarkets™

Can Eylea HD and Dupixent Profits Revive Regeneron Stock?

REGN

Zacks

8 days ago

Can Eylea HD and Dupixent Profits Revive Regeneron Stock?

REGN

The Wall Street Journal

8 days ago

Financial Services Roundup: Market Talk

'Big Short' investor Burry turned more bullish on second quarter

REGN

Reuters

8 days ago

'Big Short' investor Burry turned more bullish on second quarter

Students Earn Top Awards at 42nd Annual Research Science Institute at MIT

REGN

GlobeNewswire

9 days ago

Students Earn Top Awards at 42nd Annual Research Science Institute at MIT

REGN

Insider Monkey

10 days ago

Here’s Why You Should Consider Buying Regeneron Pharma (REGN)’s Shares

5 Insightful Analyst Questions From Regeneron’s Q2 Earnings Call

REGN

StockStory

10 days ago

5 Insightful Analyst Questions From Regeneron’s Q2 Earnings Call

REGN

StockStory

10 days ago

REGN Q2 Deep Dive: New Indications and Pipeline Progress Offset EYLEA Challenges

Amphastar Pharmaceuticals, QuidelOrtho, Integra LifeSciences, Select Medical, and Regeneron Stocks Trade Up, What You Need To Know

REGN

StockStory

11 days ago

Amphastar Pharmaceuticals, QuidelOrtho, Integra LifeSciences, Select Medical, and Regeneron Stocks Trade Up, What You Need To Know

REGN

Insider Monkey

11 days ago

Guggenheim Lifts PT on Regeneron Pharmaceuticals (REGN) to $815 From $810

REGN

Investing.com

11 days ago

Sanofi halts Praluent supply in China due to limited availability

Regeneron Reveals The Regeneron Prize For Creative Innovation 2025 Winners

REGN

Insider Monkey

11 days ago

Regeneron Reveals The Regeneron Prize For Creative Innovation 2025 Winners

3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

REGN

Zacks

12 days ago

3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

REGN

MT Newswires

12 days ago

Truist Securities Adjusts Regeneron Pharmaceuticals Price Target to $812 From $940, Maintains Buy Rating

Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments

REGN

PR Newswire

12 days ago

Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments

Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus

REGN

Zacks

15 days ago

Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus

REGN

Morningstar Research

15 days ago

Analyst Report: Intellia Therapeutics, Inc.

REGN

Insider Monkey

15 days ago

BMO Capital Lifts PT on Regeneron Pharmaceuticals (REGN) Stock, Keeps Outperform

Regeneron Announces Investor Conference Presentations

REGN

GlobeNewswire

15 days ago

Regeneron Announces Investor Conference Presentations

Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y

REGN

Zacks

17 days ago

Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y

REGN

Morningstar Research

17 days ago

Analyst Report: Sanofi

Cisco Reinvents Digital Resilience for the Agentic Era at Splunk .conf25

REGN

PR Newswire

18 days ago

Cisco Reinvents Digital Resilience for the Agentic Era at Splunk .conf25

Onco360® Has Been Selected as a Specialty Pharmacy Partner for LYNOZYFIC™ (linvoseltamab-gcpt)

REGN

GlobeNewswire

18 days ago

Onco360® Has Been Selected as a Specialty Pharmacy Partner for LYNOZYFIC™ (linvoseltamab-gcpt)

REGN

MT Newswires

19 days ago

UBS Adjusts Regeneron Pharmaceuticals Price Target to $595 From $584, Maintains Neutral Rating

REGN

MT Newswires

19 days ago

Guggenheim Adjusts Price Target on Regeneron Pharmaceuticals to $815 From $810, Maintains Buy Rating

REGN

MT Newswires

19 days ago

Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $785 From $804, Maintains Buy Rating

Manufacturing issues at Novo facility disrupt Regeneron drug review

REGN

Pharmaceutical Technology

19 days ago

Manufacturing issues at Novo facility disrupt Regeneron drug review

REGN

StockStory

23 days ago

Regeneron (REGN) Q2 Earnings: What To Expect

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025

REGN

GlobeNewswire

24 days ago

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025

Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates

REGN

Zacks

24 days ago

Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates

REGN

Zacks

25 days ago

Unlocking Q2 Potential of Regeneron (REGN): Exploring Wall Street Estimates for Key Metrics

Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth

REGN

Zacks

a month ago

Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth

REGN

Insider Monkey

a month ago

Canaccord Reiterates a Buy Rating on Regeneron Pharmaceuticals (REGN)

2 Healthcare Stocks That Are Losing to the S&P 500 This Year

REGN

Motley Fool

a month ago

2 Healthcare Stocks That Are Losing to the S&P 500 This Year

REGN

Insider Monkey

a month ago

Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory

REGN

Insider Monkey

a month ago

Longleaf Partners Fund Increased its Holdings in Regeneron Pharmaceuticals (REGN) on a Dip

Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation

REGN

GlobeNewswire

a month ago

Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation

3 Low-Volatility Stocks We Steer Clear Of

REGN

StockStory

a month ago

3 Low-Volatility Stocks We Steer Clear Of

TOP SCIENCE TEACHERS ANNOUNCED FOR 12TH ANNUAL REGENERON STEM TEACHING FELLOWSHIP

REGN

PR Newswire

a month ago

TOP SCIENCE TEACHERS ANNOUNCED FOR 12TH ANNUAL REGENERON STEM TEACHING FELLOWSHIP

Atopic Dermatitis Market Forecast Report 2025-2034 | FDA Approval of Tralokinumab-Ldrm Stimulates Treatment Advances

REGN

GlobeNewswire

a month ago

Atopic Dermatitis Market Forecast Report 2025-2034 | FDA Approval of Tralokinumab-Ldrm Stimulates Treatment Advances

AstraZeneca Plans to Invest $50 Billion in U.S. by 2030

REGN

The Wall Street Journal

a month ago

AstraZeneca Plans to Invest $50 Billion in U.S. by 2030

Health Canada extends Evkeeza approval for children with HoFH

REGN

Pharmaceutical Technology

a month ago

Health Canada extends Evkeeza approval for children with HoFH

1 Healthcare Stock on Our Buy List and 2 to Brush Off

REGN

StockStory

a month ago

1 Healthcare Stock on Our Buy List and 2 to Brush Off

Ascites Market Analysis and Forecasts Report 2025-2035 | Market Surges Amid Rising Liver Disease and Cancer Prevalence

REGN

GlobeNewswire

a month ago

Ascites Market Analysis and Forecasts Report 2025-2035 | Market Surges Amid Rising Liver Disease and Cancer Prevalence

Myopic Macular Degeneration Market Analysis and Forecast Report 2025-2035 | Advancements in Anti-VEGF Therapies Driving Progress in Treatments

REGN

GlobeNewswire

a month ago

Myopic Macular Degeneration Market Analysis and Forecast Report 2025-2035 | Advancements in Anti-VEGF Therapies Driving Progress in Treatments

Wet Age-Related Macular Degeneration (Wet AMD) Market Analysis Report 2025-2035 | Long-Acting Therapies, AI Diagnostics, and Personalized Medicine Set to Redefine the Future Landscape

REGN

GlobeNewswire

a month ago

Wet Age-Related Macular Degeneration (Wet AMD) Market Analysis Report 2025-2035 | Long-Acting Therapies, AI Diagnostics, and Personalized Medicine Set to Redefine the Future Landscape

REGN

MT Newswires

a month ago

UBS Raises Price Target on Regeneron Pharmaceuticals to $584 From $560, Keeps Neutral Rating

REGN

Insider Monkey

a month ago

Regeneron (REGN) Scores FDA Approval, JP Morgan Reaffirms $800 Price Target

Biologic Competition, Payer Pressures, and Gene Therapy Momentum Define a Pivotal Moment in nAMD and DME Management, According to Spherix Global Insights

REGN

GlobeNewswire

a month ago

Biologic Competition, Payer Pressures, and Gene Therapy Momentum Define a Pivotal Moment in nAMD and DME Management, According to Spherix Global Insights

REGN

MT Newswires

a month ago

Morgan Stanley Adjusts Price Target on Regeneron Pharmaceuticals to $754 From $755, Maintains Overweight Rating

MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer

REGN

Business Wire

a month ago

MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer

Regeneron’s Blockbuster Dupixent Faces a New Rival

REGN

Barrons.com

a month ago

Regeneron’s Blockbuster Dupixent Faces a New Rival

The Next Moderna? This Clinical-Stage Biotech Has Breakout Potential.

REGN

Barchart

a month ago

The Next Moderna? This Clinical-Stage Biotech Has Breakout Potential.

Regeneron’s Lynozyfic Gains Accelerated FDA Approval for Multiple Myeloma

REGN

Insider Monkey

a month ago

Regeneron’s Lynozyfic Gains Accelerated FDA Approval for Multiple Myeloma

Apogee Dives. But It Could Eventually Rival Sanofi's Biggest Moneymaker.

REGN

Investor's Business Daily

2 months ago

Apogee Dives. But It Could Eventually Rival Sanofi's Biggest Moneymaker.

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

REGN

CNW Group

2 months ago

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

Intellia Gains 29.8% in a Month: How Should You Play the Stock?

REGN

Zacks

2 months ago

Intellia Gains 29.8% in a Month: How Should You Play the Stock?

REGN

MT Newswires

2 months ago

RBC Raises Price Target on Regeneron Pharmaceuticals to $688 From $662, Keeps Sector Perform Rating

REGN

Motley Fool

2 months ago

2 Beaten-Down Stocks to Buy and Hold

FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug

REGN

Zacks

2 months ago

FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug

Regeneron nabs dosing edge with Lynozyfic’s FDA approval in multiple myeloma

REGN

Pharmaceutical Technology

2 months ago

Regeneron nabs dosing edge with Lynozyfic’s FDA approval in multiple myeloma

REGN

Insider Monkey

2 months ago

Regeneron Pharmaceuticals (REGN) and Sanofi Announce Approval of Dupixent® By US FDA

Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment

REGN

The Wall Street Journal

2 months ago

Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment

$Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma$

REGN

GlobeNewswire

2 months ago

Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

REGN

Zacks

2 months ago

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

REGN

Morningstar Research

2 months ago

Analyst Report: Regeneron Pharmaceuticals, Inc.

Heart Drug Stock Rockets 20% On Sales, Boosts Outlook; Regeneron Pharma's Global Partnership Is Strong Tailwind

REGN

Investor's Business Daily

2 months ago

Heart Drug Stock Rockets 20% On Sales, Boosts Outlook; Regeneron Pharma's Global Partnership Is Strong Tailwind

Anne Wojcicki's nonprofit gets court approval to buy 23andMe for $305 million

REGN

Associated Press Finance

2 months ago

Anne Wojcicki's nonprofit gets court approval to buy 23andMe for $305 million

REGN

Simply Wall St.

2 months ago

Regeneron Pharmaceuticals (NasdaqGS:REGN) Exits Multiple Russell Growth Indices

Former 23andMe CEO regains company control as $305m sale to nonprofit approved

REGN

Medical Device Network

2 months ago

Former 23andMe CEO regains company control as $305m sale to nonprofit approved

Circle initiated, Disney upgraded: Wall Street's top analyst calls

REGN

The Fly

2 months ago

Circle initiated, Disney upgraded: Wall Street's top analyst calls

REGN

MT Newswires

2 months ago

Argus Research Downgrades Regeneron Pharmaceuticals to Hold From Buy

REGN

Argus Research

2 months ago

Analyst Report: Regeneron Phars, Inc

REGN

Argus Research

2 months ago

Market Digest: REGN

Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025

REGN

GlobeNewswire

2 months ago

Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025

Regeneron Launches $200 Million Donation Matching Program to Support Vision Care

REGN

Insider Monkey

2 months ago

Regeneron Launches $200 Million Donation Matching Program to Support Vision Care

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?

REGN

Zacks

2 months ago

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?

Sanofi Trades Below 50 & 200-Day Moving Averages: Time to Buy the Dip?

REGN

Zacks

2 months ago

Sanofi Trades Below 50 & 200-Day Moving Averages: Time to Buy the Dip?

Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization

REGN

GlobeNewswire

2 months ago

Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization

REGN

Insider Monkey

2 months ago

UBS Lowers Price Target On Regeneron Pharmaceuticals, Inc. (REGN).

The Top 5 Analyst Questions From Regeneron’s Q1 Earnings Call

REGN

StockStory

2 months ago

The Top 5 Analyst Questions From Regeneron’s Q1 Earnings Call

REGN

StockStory

2 months ago

Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology Stocks

The Score: 23andMe, U.S. Steel, Accenture and More Stocks That Defined the Week

REGN

The Wall Street Journal

2 months ago

The Score: 23andMe, U.S. Steel, Accenture and More Stocks That Defined the Week

Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says

REGN

Reuters

2 months ago

Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says

From $6B Valuation to Bankruptcy to Rescue: Wojcicki Reclaims 23andMe for $305M

REGN

Benzinga

2 months ago

From $6B Valuation to Bankruptcy to Rescue: Wojcicki Reclaims 23andMe for $305M

Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid

REGN

Zacks

2 months ago

Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid

REGN

MT Newswires

2 months ago

Sector Update: Health Care

REGN

MT Newswires

2 months ago

Regeneron, Sanofi Say US FDA Approves Dupixent for Rare Skin Condition Disease

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

REGN

GlobeNewswire

2 months ago

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

REGN

Simply Wall St.

2 months ago

Shareholders Approve Bylaw Amendments at Regeneron Pharmaceuticals (NasdaqGS:REGN) Annual Meeting

REGN

Insider Monkey

2 months ago

Latest Regeneron Pharmaceuticals Inc. (REGN) News on August 23, 2025

Share on Social Networks: